scholarly journals A national surveillance project on chronic kidney disease management in Canadian primary care: a study protocol

BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e016267 ◽  
Author(s):  
Aminu K Bello ◽  
Paul E Ronksley ◽  
Navdeep Tangri ◽  
Alexander Singer ◽  
Allan Grill ◽  
...  

IntroductionEffective chronic disease care is dependent on well-organised quality improvement (QI) strategies that monitor processes of care and outcomes for optimal care delivery. Although healthcare is provincially/territorially structured in Canada, there are national networks such as the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) as important facilitators for national QI-based studies to improve chronic disease care. The goal of our study is to improve the understanding of how patients with chronic kidney disease (CKD) are managed in primary care and the variation across practices and provinces and territories to drive improvements in care delivery.Methods and analysisThe CPCSSN database contains anonymised health information from the electronic medical records for patients of participating primary care practices (PCPs) across Canada (n=1200). The dataset includes information on patient sociodemographics, medications, laboratory results and comorbidities. Leveraging validated algorithms, case definitions and guidelines will help define CKD and the related processes of care, and these enable us to: (1) determine prevalent CKD burden; (2) ascertain the current practice pattern on risk identification and management of CKD and (3) study variation in care indicators (eg, achievement of blood pressure and proteinuria targets) and referral pattern for specialist kidney care. The process of care outcomes will be stratified across patients’ demographics as well as provider and regional (provincial/territorial) characteristics. The prevalence of CKD stages 3–5 will be presented as age–sex standardised prevalence estimates stratified by province and as weighted averages for population rates with 95% CIs using census data. For each PCP, age–sex standardised prevalence will be calculated and compared with expected standardised prevalence estimates. The process-based outcomes will be defined using established methods.Ethics and disseminationThe CPCSSN is committed to high ethical standards when dealing with individual data collected, and this work is reviewed and approved by the Network Scientific Committee. The results will be published in peer-reviewed journals and presented at relevant national and international scientific meetings.

2016 ◽  
Vol 25 (2) ◽  
pp. 223-230 ◽  
Author(s):  
Ingrid Gergei ◽  
Jens Klotsche ◽  
Rainer P. Woitas ◽  
Lars Pieper ◽  
Hans-Ulrich Wittchen ◽  
...  

2017 ◽  
Vol 7 (2) ◽  
pp. 132-137
Author(s):  
Abdul Latif ◽  
Muhammad Rafiqul Alam ◽  
Asia Khanam ◽  
Farhana Hoque ◽  
Muhammad Abdur Rahim ◽  
...  

Background: Anemia is common in patients with chronic kidney disease (CKD) and this is generally anemia of chronic disease, but iron deficiency anemia (IDA) is also common. Soluble transferrin receptor (sTfR) is a useful marker for IDA. Present study was undertaken to assess the utility of sTfR as a marker of IDA in selected group of Bangladeshi patients with CKD.Methods: This cross-sectional study was conducted in the Department of Nephrology, BSMMU, Dhaka, Bangladesh from January 2013 to December 2014. Patients with anemia admitted in nephrology department whether on hemodialysis or not and medicine department of BSMMU were taken for study. The study population was further divided into two groups; Group A, patients who are having IDA and Group B, patients with ACD and a control group was also selected. Data were collected by face to face interview and laboratory investigations with a self-administered questionnaire.Results: The mean age of the patients in two study groups were 38.40±13.23 and 34.85±10.52 years respectively and male-female ratio were 0.5:1 and 1:0.5. Mean sTfR level was higher (4.81± 1.64 ?g/ml) in patients with IDA than (2.89±1.40 ?g/ml) in patients with ACD (p <0.0001). In our study mean ferritin level was 599.59± 449.15?g/L in ACD patients whereas 101.23±119.42 in IDA patients (p<0.0001). Total iron binding capacity (TIBC) was more in ACD patients with sTfRe”3?g/ml as compared to ACD patients with sTfR<3?g/ml. Transferrin saturation (TSAT) level was significantly decreased in ACD patients with sTfR ?3?g/ml as compared to ACD patients with sTfR<3?g/ml.Conclusion: sTfR has a comparable ability to S. ferritin in diagnosing IDA and ACD. However, sTfR and serum ferritin alone cannot definitely exclude co-existing iron deficiency in ACD. As sTfR is not affected by infection and/or inflammation, thus providing a non-invasive alternative to bone marrow study.Birdem Med J 2017; 7(2): 132-137


2016 ◽  
pp. gfw208 ◽  
Author(s):  
Meghan J. Elliott ◽  
Sarah Gil ◽  
Brenda R. Hemmelgarn ◽  
Braden J. Manns ◽  
Marcello Tonelli ◽  
...  

2018 ◽  
Vol 64 ◽  
Author(s):  
O.V. Demchuk ◽  
D.A. Slobodian ◽  
А.A. Piddubna ◽  
V.V. Vivsiannyk ◽  
M.A. Vintonyak

The article deals with literature data on the theory of progression of patients with chronic kidney disease with the presence of lesions of the gastroduodenal region and chronic pyelonephritis in association with metabolic syndrome. The methods of treating these diseases are presented, because this, apart from actually clinical, also has a socio-economic problem.


2011 ◽  
Vol 6 (2) ◽  
pp. 334-343 ◽  
Author(s):  
Clarissa Jonas Diamantidis ◽  
Neil R. Powe ◽  
Bernard G. Jaar ◽  
Raquel Charles Greer ◽  
Misty U. Troll ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document